Vampire bat thrombolytic study findings disappoint
Despite encouraging earlier results, themuch-awaited follow-up phase III DIAS-2trial on ischemic stroke patients treated withdesmoteplase afterthe onset of symptomsdid not showany improvement inclinical response at90 days.
Despite encouraging earlier results, the much-awaited follow-up phase III DIAS-2 trial on ischemic stroke patients treated with desmoteplase after the onset of symptoms did not show any improvement in clinical response at 90 days.
In previous investigational trials, the new drug, which is derived from vampire bat saliva, was shown to have a highly specific action and to be safe and effective over a longer treatment window than tissue plasminogen activator (tPA). Dr. Werner Hacke and colleagues at the University of Heidelberg in Germany assessed patients with acute stroke who were randomized within three hours of symptom onset to receive desmoteplase or placebo. There were no statistically significant differences in response rates between low/high dose of desmoteplase or placebo (47%/36% versus 46%).
Findings appeared in the February issue of The Lancet Neurology.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
